Press release
Sarcopenia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others
Sarcopenia Pipeline
In the Sarcopenia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Sarcopenia pipeline treatment landscape of the report, click here @ Sarcopenia Pipeline- https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Sarcopenia Pipeline Report
• DelveInsight's Sarcopenia Pipeline analysis depicts a robust space with 8+ active players working to develop 8+ pipeline treatment therapies.
• The leading Sarcopenia Companies working in the market include Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
• Promising Sarcopenia Pipeline Therapies in the various stages of development include REGN1033 (SAR391786), bimagrumab, Comparator: MK-0773, Astaxanthin formulation, LPCN 1148, MYMD-1 600MG, BIO101, Beta-hydroxy-Beta-methylbutyrate and Vitamin D, and others
• On March 2023, MyMD Pharmaceuticals Inc announced a study of phase 2 clinical trials for MYMD-1 600MG. The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
• On July 2023, Australian Catholic University announced a study of phase 4 clinical trials for Pendulum WBF-038. To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography [HR-pQCT]) of the distal tibia.
Sarcopenia Overview
Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity.
To explore more information on the latest breakthroughs in the Sarcopenia Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Sarcopenia Emerging Drugs Profile
• Sarconeos (BIO101): Biophytis
• MYMD-1: MyMD Pharmaceuticals
Sarcopenia Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Sarcopenia. The Sarcopenia companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.
Request a sample and discover the recent advances in Sarcopenia Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Sarcopenia Drugs and Companies
• REGN1033 (SAR391786): Regeneron Pharmaceuticals
• Bimagrumab: Novartis Pharmaceuticals
• LPCN1148: Lipocine Inc
• MYMD-1 600MG: MyMD Pharmaceuticals
Sarcopenia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Sarcopenia Therapeutics Market include-
Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
Dive deep into rich insights for drugs for Sarcopenia Pipeline, click here for Sarcopenia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Sarcopenia Pipeline Report
• Coverage- Global
• Sarcopenia Companies- Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
• Sarcopenia Pipeline Therapies- REGN1033 (SAR391786), bimagrumab, Comparator: MK-0773, Astaxanthin formulation, LPCN 1148, MYMD-1 600MG, BIO101, Beta-hydroxy-Beta-methylbutyrate and Vitamin D, and others
• Sarcopenia Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Sarcopenia Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Sarcopenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sarcopenia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sarconeos (BIO101): Biophytis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MYMD-1: MyMD Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PF-1801: PhaseBio Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Sarcopenia Key Companies
21. Sarcopenia Key Products
22. Sarcopenia- Unmet Needs
23. Sarcopenia- Market Drivers and Barriers
24. Sarcopenia- Future Perspectives and Conclusion
25. Sarcopenia Analyst Views
26. Sarcopenia Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others here
News-ID: 3140320 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Sarcopenia
Sarcopenia Market Size, Share & Growth Analysis 2034
Sarcopenia Market Overview
Sarcopenia is a condition characterized by the progressive loss of muscle mass, strength, and function, primarily affecting the elderly. This decline leads to increased frailty, higher risk of falls, and diminished quality of life. The rising global geriatric population has heightened the prevalence of sarcopenia, making it a significant public health concern. Consequently, there is a growing demand for effective treatments and interventions to manage and mitigate the…
Sarcopenia Treatment Market Future Prediction Report By 2030
Sarcopenia Treatment Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.…
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcopenia treatment market…
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product…
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
view full report
https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic
Sarcopenia Therapeutic Market
Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
China is the largest consumption region of…
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not…
